SCHEMBL108534

SCHEMBL108534

COc1cccc(F)c1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.48
ALDH1A1 P00352 2/20 0.48
ADRA2B P18089 1/20 0.48
PTGS1 P23219 1/20 0.48
NFE2L2 Q16236 1/20 0.47
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA4 P22748 1/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
RPS6KA2 Q15349 1/20 0.43
HPGD P15428 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP3A4 P08684 2/20 0.41
MAPT P10636 2/20 0.41
MAPK1 P28482 2/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8943218 0.90 ALDH1A1 (0.42) TDP1ALDH1A1ADRA2BPTGS1NFE2L2
SCHEMBL1340782 0.83 NFE2L2 (0.41) TDP1ALDH1A1ADRA2BPTGS1NFE2L2
SCHEMBL358973 0.83 ALDH1A1 (0.59) TDP1ALDH1A1ADRA2BPTGS1CA12
SCHEMBL26606694 0.79 ALDH1A1 (0.40) TDP1ALDH1A1ADRA2BPTGS1L3MBTL1
Nitrogen SCHEMBL27853237 0.78 ALDH1A1 (0.54) TDP1ALDH1A1ADRA2BPTGS1CA12
SCHEMBL1750348 0.78 TAAR1 (0.43) TDP1ALDH1A1NFE2L2L3MBTL1KDM4E
SCHEMBL17887304 0.77 L3MBTL1 (0.55) TDP1ALDH1A1PTGS1L3MBTL1HPGD
SCHEMBL104947 0.77 MCHR1 (0.46) ALDH1A1CA1CA2CA7CA9
SCHEMBL2061557 0.77 L3MBTL1 (0.46) TDP1ALDH1A1CA2L3MBTL1HPGD
SCHEMBL196734 0.76 CA1 (0.50) TDP1ALDH1A1ADRA2BPTGS1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109904124-A QFN (quad Flat No-lead) packaging structure with short-circuit prevention function 西安航思半导体有限公司 2019-06-18 CN claimed
CN-109904131-A High stability DFN packaged device 西安航思半导体有限公司 2019-06-18 CN claimed
CN-109904125-A The preparation method of high temperature resistant QFN encapsulating structure 西安航思半导体有限公司 2019-06-18 CN claimed
CN-106083536-B A kind of preparation method of Ansai Qu key intermediate 浙江永太科技股份有限公司 2018-10-30 CN claimed
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them ROSSI CRISTINA 2008-08-28 US claimed
EP-1868997-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM Menarini International Operations Luxembourg S.A. (LU) 2007-12-26 EP claimed
WO-2006097460-A1 HYDROXAMATES AS HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL FORMULATIONS CONTAINING THEM MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) 2006-09-21 WO claimed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP claimed
EP-4651944-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2025-11-26 EP disclosed
EP-4223759-B1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO LTD (CN) 2025-06-11 EP disclosed
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2025-05-15 US disclosed
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) 2025-04-17 US disclosed
CN-113490668-B Compounds and compositions for the treatment of diseases associated with APJ receptor activity 安娜普尔纳生物股份有限公司 2025-02-25 CN disclosed
CN-119365192-A Heteroaryl compounds as HPK1 inhibitors and methods of use thereof 深圳市原力深湾创新药有限公司 2025-01-24 CN disclosed
US-5723475-A Arylpiperidine and arylpiperazine derivatives and medicament containing the same SUNTORY LIMITED (JP) 1998-03-03 US disclosed
EP-0757986-A1 ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-12 EP disclosed
EP-0249043-B1 QUINOLINECARBOXYLIC ACID DERIVATIVES NIPPON SHINYAKU COMPANY, LIMITED (JP) 1993-08-04 EP disclosed
US-5086049-A Bactericides NIPPONSHINYAKU CO., LTD. (JP) 1992-02-04 US disclosed
US-4843070-A BACTERIDCIDES, FUNGICIDES NIPPON SHINYAKU CO., LTD. (JP) 1989-06-27 US disclosed
EP-0249043-A2 Quinolinecarboxylic acid derivatives NIPPON SHINYAKU COMPANY, LIMITED (JP) 1987-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207694-A1 Hydroxamates as Histone Deacetylase Inhibitors and Pharmaceutical Formulations Containing Them HDAC1, HDAC8, HDAC9 TDP1 1693/4885ALDH1A1 1106/4885ADRA2B 4275/4885
US-20250154169-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 TDP1 406/4885ALDH1A1 3559/4885ADRA2B 3808/4885
US-20250122174-A1 Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same SGK1, HYPK, PCK1 TDP1 1421/4885ALDH1A1 3596/4885ADRA2B 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.